OAM
BCRX icon

OP Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

OP Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
1,340,990
+88,127
+7% +$797K 0.14% 117
2026
Q1 		$11.9M Buy
1,252,863
+1,113,656
+800% +$8.65M 0.12% 114
2025
Q4 		$1.09M Buy
+139,207
New +$1.01M 0.01% 580

Other funds holding BCRX

NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
QFW
QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CV
Counterweight Ventures Wilmington, North Carolina $201M AUM 35.56% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

OP Asset Management's BCRX Position: Q2 2026 in Review

OP Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 7% in Q2 2026, buying an estimated $797K and bringing the position to 1,340,990 shares worth $13.4M. The position accounts for 0.14% of the portfolio, ranked #117.

OP Asset Management first reported a position in BCRX in Q4 2025 and has held it in 3 quarters since. 52 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • OP Asset Management held 1,340,990 shares of BioCryst Pharmaceuticals worth $13.4M as of Q2 2026.
  • OP Asset Management bought 88,127 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $797K.
  • BioCryst Pharmaceuticals made up 0.14% of OP Asset Management's portfolio in Q2 2026, its #117 holding.
  • OP Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 52 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.